上海医药2005年第三季度报告（节录）_医药资讯

财务资料1、主要会计数据及财务指标币种:人民币本报告期末上年度期末本报告期末比上年度期末增减（％）总资产(元)7,202,318,300.086,464,172,264.1211.42股东权益(不含少数股东权益)(元)1,801,116,495.781,763,288,884.242.15每股净资产(元)3.803.722.15调整后的每股净资产(元)3.453.46-0.41报告期年初至报告期期末本报告期比上年同期增减（％）经营活动产生的现金流量净额(元)-33,036,831.90每股收益(元)0.050.16-21.22净资产收益率(%)1.284.13减少0.35个百分点扣除非经常性损益后的净资产收益率(%)1.193.37减少0.43个百分点非经常性损益项目金额(元)处置除公司产品外的其他资产产生的损益12,118,670.81各种形式的政府补贴2,200,843.73短期投资收益-25,773.94扣除资产减值准备后的其他各项营业外收入、支出-594,042.83合计13,699,697.772、利润表单位:元 币种:人民币 审计类型:未经审计项目合并母公司本期数(7-9月)上年同期数(7-9月)本期数(7-9月)上年同期数(7-9月)一、主营业务收入3,201,807,416.732,547,705,786.641,719,346,517.101,227,688,158.71减：主营业务成本2,983,893,527.672,323,170,078.151,651,938,301.701,172,774,009.09主营业务税金及附加4,903,052.265,400,190.052,269,647.382,735,725.00二、主营业务利润（亏损以“-”号填列）213,010,836.80219,135,518.4465,138,568.0252,178,424.62加：其他业务利润（亏损以“-”号填列）2,634,459.566,747,621.69310,746.81100,486.04减:营业费用109,655,772.49115,345,690.8937,236,819.0735,044,127.02管理费用67,913,412.3385,695,043.9914,736,957.319,831,056.40财务费用12,147,566.48-7,134,639.607,236,134.36-11,618,257.64三、营业利润（亏损以“-”号填列）25,928,545.0631,977,044.856,239,404.0919,021,984.88加：投资收益（损失以“-”号填列）3,011,685.9414,316,512.3712,826,620.0713,037,444.07补贴收入1,077,022.00744,830.33315,000.00315,000.00营业外收入1,805,545.05582,439.621,494,830.8612,273.66减：营业外支出864,059.791,335,617.9469,053.181,903.41四、利润总额（亏损总额以“-”号填列）30,958,738.2646,285,209.2320,806,801.8432,384,799.20减：所得税3,898,183.3910,826,813.96-2,303,046.043,050,006.58减：少数股东损益3,950,706.986,123,602.65加：未确认投资损失(合并报表填列)五、净利润（亏损以“-”号填列）23,109,847.8829,334,792.6223,109,847.8829,334,792.62单位:元 币种:人民币 审计类型:未经审计项目合并母公司本期数(1-9月)上年同期数(1-9月)本期数(1-9月)上年同期数(1-9月)一、主营业务收入9,267,956,474.708,118,337,461.364,845,154,625.004,112,142,996.59减：主营业务成本8,608,462,400.037,383,098,075.234,643,532,485.103,922,624,409.65主营业务税金及附加15,866,947.9117,205,130.127,277,022.328,117,478.35二、主营业务利润（亏损以“-”号填列）643,627,126.76718,034,256.01194,345,117.58181,401,108.59加：其他业务利润（亏损以“-”号填列）47,033,139.3921,814,602.1929,224,442.89828,219.00减:营业费用342,220,556.61341,836,051.23118,756,934.1386,858,721.90管理费用236,980,837.45265,885,348.7069,904,992.6636,704,498.55财务费用10,445,408.844,848,254.49-3,398,342.85-10,390,401.26三、营业利润（亏损以“-”号填列）101,013,463.25127,279,203.7838,305,976.5369,056,508.40加：投资收益（损失以“-”号填列）-5,200,658.1940,206,103.8625,681,062.9858,882,890.89补贴收入3,258,028.004,733,156.35804,400.00315,000.00营业外收入17,188,534.2912,410,348.4714,815,901.311,070,562.56减：营业外支出4,643,521.723,213,145.971,204,049.81339,609.31四、利润总额（亏损总额以“-”号填列）111,615,845.63181,415,666.4978,403,291.01128,985,352.54减：所得税25,386,562.6934,879,146.513,977,840.1910,750,147.28减：少数股东损益11,803,832.1228,301,314.72加：未确认投资损失(合并报表填列)五、净利润（亏损以“-”号填列）74,425,450.82118,235,205.2674,425,450.82118,235,205.26 详见《上海市医药股份有限公司2005年第三季度报告》（据“上海证券交易所”；医药网整理，严禁转载） 医药网新闻